Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Completion of the Second Placing
March 04, 2014 11:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
COMPLETION OF THE SECOND PLACING
Oxford, UK, 4 March 2014 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announced on 28 February 2014 that it had gained shareholder approval to raise £22.0 million through the issue of new ordinary shares of 1 penny each ('New Shares'). Admission to trading on AIM of the New Shares is taking place in two stages (the 'First Placing' and the 'Second Placing').
On 3 March 2014, the Company announced that the First Placing was completed. Today, the Company announces that the Second Placing has also been completed following the admission of the final tranche of shares to trading on AIM.
Following completion of the Second Placing the Company has 821,228,226 ordinary shares in issue. This figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.
Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 939 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)207 7148 7900 |